Monalizumab

Monalizumab

Monalizumab

Monoclonal antibody

Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]

Quick Facts Monoclonal antibody, Type ...

Mechanism of action

Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]

References

  1. [1]
    A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
  2. [2]
    IPH2201 studies
  3. [3]
    First Clinical Data For Monalizumab As A Single Agent In Cancer Patients Show Favorable Safety Profile
  4. [4]
    AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips
  5. [5]
    "monalizumab". Archived from the original on 2016-12-20. Retrieved 2016-12-09.
  6. [6]
    van Hall T, André P, Horowitz A, Ruan DF, Borst L, Zerbib R, Narni-Mancinelli E, van der Burg SH, Vivier E (October 2019). "Monalizumab: inhibiting the novel immune checkpoint NKG2A". Journal for Immunotherapy of Cancer. 7 (1): 263. doi:10.1186/s40425-019-0761-3. PMC 6798508. PMID 31623687.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Monalizumab, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.